Actofi Pharma And Research Profile
Key Indicators
- Authorised Capital ₹ 8.50 Cr
as on 07-11-2024
- Paid Up Capital ₹ 4.13 Cr
as on 07-11-2024
- Company Age 3 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 9.80 Cr
as on 07-11-2024
- Revenue %
(FY 2023)
- Profit 13.83%
(FY 2023)
- Ebitda 80.95%
(FY 2023)
- Net Worth -95.24%
(FY 2023)
- Total Assets 92.35%
(FY 2023)
About Actofi Pharma And Research
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 8.50 Cr and a paid-up capital of Rs 4.13 Cr.
The company currently has active open charges totaling ₹9.80 Cr.
Truptiben Patel, Charmi Radadia, Utsav Patel, and One other member serve as directors at the Company.
- CIN/LLPIN
U24239GJ2021PTC123068
- Company No.
123068
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
03 Jun 2021
- Date of AGM
07 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Gandhi Nagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Actofi Pharma And Research?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Truptiben Patel  | Director | 03-Jun-2021 | Current |
| Charmi Radadia | Director | 16-Dec-2021 | Current |
| Utsav Patel | Director | 03-Jun-2021 | Current |
| Abhi Agarwal | Director | 11-Jan-2022 | Current |
Financial Performance of Actofi Pharma And Research.
Actofi Pharma And Research Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 13.83% increase in profit. The company's net worth observed a substantial decline by a decrease of 95.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Actofi Pharma And Research?
Unlock access to Actofi Pharma And Research's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
- Kavach 9 Pharma & Research Private LimitedActive 10 years 2 months
Charmi Radadia is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 27 Aug 2024 | ₹8.00 Cr | Open |
Sidbi Creation Date: 27 Aug 2024 | ₹1.80 Cr | Open |
How Many Employees Work at Actofi Pharma And Research?
Actofi Pharma And Research has a workforce of 0 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Actofi Pharma And Research, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Actofi Pharma And Research's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
